Abstract p53, encoded by the tumor suppressor gene TP53, is one of the most important
tumor suppressor factors in vivo and can be negatively regulated by MDM2 through p53 …

Design of small-molecule inhibitors (MDM2 inhibitors) to block the MDM2–p53 protein–
protein interaction has been pursued as a new cancer therapeutic strategy. In recent years …

A palladium-catalyzed enantioselective α-allylation of deconjugated butenolides with aza-π-
allylpalladium 1, 4-diploes, in situ generated from palladium-mediated decarboxylation of …

Cancer is known as one of the main causes of death in the world; and many compounds
have been synthesized to date with potential use in cancer therapy. Thiazole is a versatile …

The tumor suppressor p53 is one of the most important proteins for protection of genomic
stability and cancer prevention. Cancers often inactivate it by either mutating its gene or …

As a result of the toxicity of currently available anticancer drugs and the inefficiency of
chemotherapeutic treatments, the design and discovery of effective and selective antitumor …

A recent therapeutic strategy in oncology is based on blocking the protein–protein
interaction between the murine double minute (MDM) homologues MDM2/X and the tumor …

The growth inhibitory activity of p53 tumor suppressor is tightly regulated by interaction with
two negative regulatory proteins, murine double minute 2 (MDM2) and X (MDMX), which are …

The interaction between the tumor suppressor protein p53 and its negative regulator, the
MDM2 oncogenic protein, has gained significant attention in cancer drug discovery. In this …

Potent and selective small-molecule inhibitors of the p53-MDM2 interaction intended for the
treatment of p53 wild-type tumors have been designed and optimized in a number of …